Study type: Human research · Status: Verified against declared source

Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection.

PloS one · 2016

Study scale: Nucleic acid polymers (NAPs) have both entry and post-entry antiviral activity in duck hepatitis B virus (DHBV) infected Pekin duck hepatocytes in vitro and in vivo [11, 12].

Abstract only: Open source record

Product or molecular entity relationships

Thymosin Alpha 1: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

A small proof of concept trial (REP 101 study) with REP 2055 monotherapy was initiated in Bangladeshi patients with HBeAg positive chronic HBV infection.

Methods

Nucleic acid polymers (NAPs) have both entry and post-entry antiviral activity in duck hepatitis B virus (DHBV) infected Pekin duck hepatocytes in vitro and in vivo [11, 12].

Scale or participants

Nucleic acid polymers (NAPs) have both entry and post-entry antiviral activity in duck hepatitis B virus (DHBV) infected Pekin duck hepatocytes in vitro and in vivo [11, 12].

Key findings

Previous in vivo studies have suggested that nucleic acid polymers (NAPs) may reduce circulating levels of HBsAg in the blood by blocking its release from infected hepatocytes and that this effect may have clinical benefit.

Limitations and uncertainty

HBsAg reduction was accompanied by the appearance of anti-HBs > 10 mU / ml in all patients (Fig 3B) and the levels observed generally correlated with the speed and magnitude of HBsAg clearance (Fig 3A).

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.